We also support the development of effective business models, enable collaborations and develop financing mechanisms, all with the objective of ensuring wide scale-up of solutions that can deliver extensive and significant outcomes in healthcare.
Accelerating lab to last mile journey of innovations
Building collaborations
Catalyzing and aggregating funds
our partners around the world.
Health System and Access
Management
Partnerships
their adoption in the health system.
Our long-term impact is in the outcomes achieved through adoption of these solutions by the health system.
Close to 25,000 chest X-rays were processed through qXR. Out of the general population screened in hotspots and containment zones, as well as among contacts of COVID-19 patients, about 20% were instantly reported by qXR as having COVID-19 indications and were immediately recommended for next steps in the patient management. These included asymptomatic cases which make up over 50% of the population. Further usage of qXR for screening and triaging COVID-19 suspects helped optimal utilization of limited RT-PCR kits. Based on preliminary analysis for which RT-PCR results were available from ICMR, an yield of 90.8% was observed using qXR. This proved qXR to be an effective triaging tool for COVID-19. qXR was also used by doctors to monitor disease progression.
Tracking Innovations for Greater Impact
Since our inception, we have de-risked the development of over 14 innovations and our portfolio companies have contributed immensely in efforts to control and eliminate infectious diseases such as malaria and TB. Through rigorous investment and strategic guidance, India Health Fund has facilitated the development and deployment of their innovations in infectious diseases, moving them closer to the last mile. Many of these innovations are already touching lives.
Our Technology Readiness Level (TRL) Tracker Tool serves as a reminder to the progress achieved, and the path that lies ahead.
Close to 25,000 chest X-rays were processed through qXR. Out of the general population screened in hotspots and containment zones, as well as among contacts of COVID-19 patients, about 20% were instantly reported by qXR as having COVID-19 indications and were immediately recommended for next steps in the patient management. These included asymptomatic cases which make up over 50% of the population. Further usage of qXR for screening and triaging COVID-19 suspects helped optimal utilization of limited RT-PCR kits. Based on preliminary analysis for which RT-PCR results were available from ICMR, an yield of 90.8% was observed using qXR. This proved qXR to be an effective triaging tool for COVID-19. qXR was also used by doctors to monitor disease progression.
Officer, Tata Trusts)